ZVRA Q1 2022 Earnings — Zevra Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ZVRAZevra Therapeutics, Inc.

$618M

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M-67.3% YoY

Gross Profit

$4M99.8% margin

Operating Income

-$2M-46.9% margin

Net Income

-$2M-47.0% margin

EPS (Diluted)

$-0.05

QoQ Revenue Growth

+53.6%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$4M

Stock-Based Comp.

$918,000

Balance Sheet

Total Assets

$126M

Total Liabilities

$4M

Stockholders' Equity

$121M

Cash & Equivalents

$100M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$12M	-67.3%
Gross Profit	$4M	$11M	-64.4%
Operating Income	-$2M	$7M	-126.7%
Net Income	-$2M	-$10M	+81.9%